Autologous, engineered T Cells targeting TP53 R248Q therapy(Shanghai Jiao Tong University Affiliated First People'S Hospital)

N/A

Report date: 2024/10/11 20:00:59

Base Information

Drug NameAutologous, engineered T Cells targeting TP53 R248Q therapy(Shanghai Jiao Tong University Affiliated First People'S Hospital)
Drug Alias NameTP53 R248Q Mutation-specific TCR-T Cell Therapy(Shanghai Jiao Tong University Affiliated First People'S Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionTumor protein p53 modulatorsT lymphocyte replacements
TargetsTumor protein p53
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Jiao Tong University Affiliated First People'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jiao Tong University Affiliated First People'S Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A